Prioritis, an IQVIA business undertakes support for pricing and reimbursement processes for new innovative drugs, extension of indications and reassessment of therapeutic areas. The company approach is highly appreciated by leading Global and European heads of market access and our methodology has become the industry standard, adopted in the majority of requests for proposals.
In-house writing dossier requires extremely specialized skills which our team guarantees thanks to its manpower and resources. Our consultants are able to understand the detailed situations faced by clients’ products kpi’s and to handle the most strategic missions.
Prioritis has proven its ability to compile dossiers for submission to national evaluation agencies, by assisting its clients in their interactions with the authorities at all stages:
Prioritis assists pricing and market access teams at every stage of a product’s life:
Our expert team is able to analyze the efficacy and therapeutic value of each drug, its position in the market, its price expectation, levels of reimbursement and resulting impact on financial forecast.
Complex situations need a unique approach and Prioritis offers the best expert guidance:
Prioritis has developed an extensive network of KOLs and shares a unique relationship with national and local payers across all key markets.
These Ad board meetings enable our clients to: